Axsome Therapeutics, Inc (AXSM) Financials
Key financial figures for Axsome Therapeutics, Inc (Q3 2026).
Axsome Q3 2026 total revenue of $259.7 million rose 52% year over year, and the net loss narrowed to $12.9 million ($(0.25) per share) from $47.2 million ($(0.94)). Total revenue was $259.7 million (the release's "total net product revenue"), up 52% from $171.0 million in Q3 2025; the company said the quarter put it past a one-billion-dollar annual run rate. AUVELITY net product sales were $207.6 million (+53% from $136.1 million). SUNOSI net product revenue was $48.2 million (+47% from $32.8 million) and included $8.5 million of milestone revenue and $1.2 million of royalties; SUNOSI net product sales alone were $38.5 million. SYMBRAVO net product sales were $3.9 million (+88% from $2.1 million). On the outlook: No numeric financial guidance in the release. Management stated that current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan. Figures are for Q3 2026, as Axsome Therapeutics Inc. reported them.
- Revenue
- $260M
- Net Income
- -$13M
- EPS
- $-0.25
- Total Assets
- $827M
- Operating Cash Flow
- -$9M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $260M | -$13M | -$0.25 | -4.26% | -$10M |
| Q2 FY2026 | $218M | -$51M | -$0.99 | -22.73% | |
| Q1 FY2026 | $191M | -$65M | -$1.26 | -33.14% | -$21M |
| Q4 FY2025 | $196M | -$29M | -$0.56 | -15.02% | -$19M |
| Q3 FY2025 | $171M | -$47M | -$0.94 | -26.97% | $988K |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $638M | -$183M | -$3.68 | -26.51% | -$94M |
| FY2024 | $386M | -$287M | -$5.99 | -72.74% | -$129M |
| FY2023 | $271M | -$239M | -$5.27 | -85.67% | -$146M |
Frequently asked questions
What was Axsome Therapeutics Inc.'s revenue last quarter?
Axsome Therapeutics Inc. reported revenue of $259.7 million for Q3 FY2026, up 51.9% from the same period a year earlier.
Is Axsome Therapeutics Inc. profitable?
Not in its most recent reported period. Axsome Therapeutics Inc. reported a net loss of $12.9 million for Q3 FY2026, a net margin of -4.96% on revenue.
How has Axsome Therapeutics Inc.'s margin trended?
Operating margin was -4.26% in Q3 FY2026, compared with -26.97% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Axsome Therapeutics Inc. generate?
Axsome Therapeutics Inc. generated free cash flow of -$9.7 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Axsome Therapeutics, Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.